|
|||||
|
|
Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis |
|
| Affiliation: | aAstraZeneca India Pvt Ltd., Hebbal, Bangalore, India;bAstraZeneca UK, Macclesfield, Cheshire, England;cSwedish Institute for Communicable Disease Control, Solna, Sweden |
| Abstract: | |
| Keywords: | |